LON:HVO

Hvivo Share Forecast, Price & News

GBX 16.50
-0.88 (-5.04 %)
(As of 01/17/2020)
Add
Compare
Today's Range
16.25
17.25
50-Day Range
16.50
53.66
52-Week Range
9.75
29.20
Volume79,622 shs
Average Volume142,465 shs
Market Capitalization£13.80 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive HVO News and Ratings via Email

Sign-up to receive the latest news and ratings for Hvivo and its competitors with MarketBeat's FREE daily newsletter.


About Hvivo

hVIVO plc, a specialty biopharma company, provides medical and scientific research services in the United Kingdom, the United States, and Europe. The company is developing a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases, including influenza virus, respiratory syncytial virus, asthma exacerbation, and human rhinovirus. It also offers laboratory based research services; and target and biomarker discovery services. hVIVO plc primarily serves pharmaceutical and biotech customers. The company was formerly known as Retroscreen Virology Group plc and changed its name to hVIVO plc in April 2015. hVIVO plc was incorporated in 1988 and is based in London, the United Kingdom.

Headlines

Open Orphan Share Chat
Open Orphan Share Chat
December 16, 2020 |  lse.co.uk
Hvivo Plc Share Chat
Hvivo Plc Share Chat
January 20, 2020 |  www.lse.co.uk
Hvivo Share News (HVO)
Hvivo Share News (HVO)
January 6, 2020 |  www.lse.co.uk
HVIVO PLC
HVIVO PLC
December 19, 2019 |  www.finanznachrichten.de
Can hVIVO (LON:HVO) Afford To Invest In Growth?
Can hVIVO (LON:HVO) Afford To Invest In Growth?
October 10, 2019 |  finance.yahoo.com
Successful RSV Challenge Study in Older Adults
Successful RSV Challenge Study in Older Adults
August 6, 2019 |  markets.ft.com
See More Headlines

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-20-77561300
EmployeesN/A
Year FoundedN/A

Sales & Book Value

Annual Sales£12.09 million
Cash FlowGBX 4.90 per share
Book ValueGBX 16.50 per share

Profitability

Debt

Price-To-Earnings

Miscellaneous

Market Cap£13.80 million
Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

0.54 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Hvivo (LON:HVO) Frequently Asked Questions

What stocks does MarketBeat like better than Hvivo?

Wall Street analysts have given Hvivo a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Hvivo wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Hvivo's earnings last quarter?

Hvivo PLC (LON:HVO) announced its earnings results on Thursday, April, 19th. The company reported ($16.50) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($10.90) by $5.60.
View Hvivo's earnings history
.

How has Hvivo's stock been impacted by COVID-19?

Hvivo's stock was trading at GBX 16.50 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, HVO stock has increased by 0.0% and is now trading at GBX 16.50.
View which stocks have been most impacted by COVID-19
.

Who are Hvivo's key executives?

Hvivo's management team includes the following people:
  • Mr. Graham Edward Yeatman, Chief Financial & Bus. Officer and Company Sec. (Age 52)
  • Mr. David Robert Norwood, Strategic Consultant (Age 50)
  • Dr. Trevor Michael Phillips, Exec. Chairman & CEO (Age 58)
  • Ms. Fleur Wood, Exec. VP of Investor Relations & Communications
  • Colin Paterson, Director of Marketing, Communication & PR

Who are some of Hvivo's key competitors?

What other stocks do shareholders of Hvivo own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hvivo investors own include ValiRx (VAL), boohoo group (BOO), Petrofac (PFC), Falanx Group (FLX), IQE (IQE), Scirocco Energy Plc (SOLO.L) (SOLO), CyanConnode (CYAN), Eckoh (ECK), Enanta Pharmaceuticals (ENTA) and Lloyds Banking Group (LLOY).

What is Hvivo's stock symbol?

Hvivo trades on the London Stock Exchange (LON) under the ticker symbol "HVO."

How do I buy shares of Hvivo?

Shares of HVO and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Hvivo's stock price today?

One share of HVO stock can currently be purchased for approximately GBX 16.50.

How much money does Hvivo make?

Hvivo has a market capitalization of £13.80 million and generates £12.09 million in revenue each year.

What is Hvivo's official website?

The official website for Hvivo is hvivo.com.

Where are Hvivo's headquarters?

Hvivo is headquartered at Q M B Innovation Centre, 42 New Road, LONDON, E1 2AX, United Kingdom.

How can I contact Hvivo?

Hvivo's mailing address is Q M B Innovation Centre, 42 New Road, LONDON, E1 2AX, United Kingdom. The company can be reached via phone at +44-20-77561300.


This page was last updated on 5/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.